Oxidized low-density lipoprotein and lipoprotein(a) levels in chronic kidney disease patients under hemodialysis: Influence of adiponectin and of a polymorphism in the apolipoprotein(a) gene

Hemodialysis International

Volumn 16, Issue 4, 2012, Pages 481-490

  Ribeiro, Sandra ^a   Faria, Maria do Sameiro ^a,b   Silva, Gil ^a   Nascimento, Henrique ^c   Rocha Pereira, Petronila ^c,d   Miranda, Vasco ^b   Vieira, Emília ^e   Santos, Rosário ^e   Mendonça, Denisa ^a   Quintanilha, Alexandre ^a,c   Costa, Elísio ^c,f   Belo, Luís ^a,c   Santos Silva, Alice ^a,c  

^a UNIVERSITY OF PORTO   (Portugal)

^b FMC Dinefro Diálises e Nefrologia SA   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

^d UNIVERSITY OF BEIRA INTERIOR   (Portugal)

^e Centro de Genética Médica Doutor Jacinto de Magalhães   (Portugal)

^f CBQF CENTRO DE BIOTECNOLOGIA E QUÍMICA FINA LABORATÓRIO ASSOCIADO   (Portugal)

Author keywords

Adiponectin; Chronic kidney disease; Lipoprotein(a); Oxidized LDL; Pentanucleotide repeat polymorphism

Indexed keywords

ADIPONECTIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; AGED; APOLIPOPROTEIN A GENE; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE; GENETIC POLYMORPHISM; GENOTYPE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HOMOZYGOTE; HUMAN; LIPID ANALYSIS; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PENTANUCLEOTIDE REPEAT POLYMORPHISM; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION;

ADIPONECTIN; ADULT; AGED; APOLIPOPROTEINS A; CASE-CONTROL STUDIES; FEMALE; HUMANS; LIPIDS; LIPOPROTEINS, LDL; MALE; POLYMORPHISM, GENETIC; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84867103661     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2012.00687.x     Document Type: Article

References (36)

1. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: Effects on the cardiovascular system. Circulation. 2007; 116:85-97.
2. Wanner C, Zimmermann J, Schwedler S, Metzger T. Inflammation and cardiovascular risk in dialysis patients. Kidney Int Suppl. 2002; 61:99-102.
3. Van der Sande FM, Kooman JP, Leunissen KM. The predictive value of C-reactive protein in end-stage renal disease: Is it clinically significant? Blood Purif. 2006; 24:335-341.
4. Chawla LS, Krishnan M. Causes and consequences of inflammation on anemia management in hemodialysis patients. Hemodial Int. 2009; 13:222-234.
5. Kassimatis TI, Konstantinopoulos PA. The role of statins in chronic kidney disease (CKD): Friend or foe? Pharmacol Ther. 2009; 122:312-323.
6. Laurinavicius AG, Santos RD. Dislipidemia, estatinas e insuficiência renal crónica. Rev Bras Hipertens. 2008; 15:156-161.
7. Shurraw S, Tonelli M. Statins for treatment of dyslipidemia in chronic kidney disease. Perit Dial Int. 2006; 26:523-539.
8. Shirai S, Ominato M, Shimazu T, etal. Imbalance between production and scavenging of hydroxyl radicals in patients maintained on hemodialysis. Clin Exp Nephrol. 2005; 9:310-314.
9. Osorio A, Ortega E, de Haro T, Torres JM, Sánchez P, Ruiz-Requena E. Lipid profiles and oxidative stress parameters in male and female hemodialysis patients. Mol Cell Biochem. 2011; 353:59-63.
10. Bayés B, Pastor MC, Bonal J, etal. Homocysteine, C-reactive protein, lipid peroxidation and mortality in haemodialysis patients. Nephrol Dial Transplant. 2003; 18:106-112.
11. Ouchi N, Shibata R, Walsh K. Cardioprotection by adiponectin. Trends Cardiovasc Med. 2006; 16:141-146.
12. Shaibi GQ, Cruz ML, Weigensberg MJ, etal. Adiponectin independently predicts metabolic syndrome in overweight Latino youth. J Clin Endocrinol Metab. 2007; 92:1809-1813.
13. Enas EA, Chacko V, Senthilkumar A, Puthumana N, Mohan V. Elevated lipoprotein(a)-A genetic risk factor for premature vascular disease in people with and without standard risk factors: A review. Dis Mon. 2006; 52:5-50.
14. Lippi G, Guidi G. Lipoprotein(a): From ancestral benefit to modern pathogen? Q J Med. 2000; 93:75-84.
15. Longenecker JC, Klag MJ, Marcovina SM, etal. High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients. J Am Soc Nephrol. 2005; 16:1794-1802.
16. Rosas S, Joffe M, Wolfe M, Brayman K, Rader DJ. Effects of renal replacement therapy on plasma lipoprotein(a) levels. Am J Nephrol. 2008; 28:361-365.
17. Frischmann ME, Kronenberg F, Trenkwalder E, etal. In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients. Kidney Int. 2007; 71:1036-1043.
18. Edjème-Aké A, Garnotel R, Vallée-Polneau S, Anglés-Cano E, Monnet D, Gillery P. Relationship between apo(a) length polymorphism and lipoprotein(a) concentration in healthy Ivorian subjects with single or double apo(a) isoforms. Clin Biochem. 2008; 41:1039-1043.
19. Berglund L, Ramakrishnan R. Lipoprotein(a): An elusive cardiovascular risk factor. Arterioscler Thromb Vasc Biol. 2004; 24:2219-2226.
20. Wade DP, Clarke JG, Lindahl GE, etal. 5'control regions of the apolipoprotein(a) gene and members of the related plasminogen gene family. Proc Natl Acad Sci U S A. 1993; 90:1369-1373.
21. Ferreira H, Costa E, Vieira E, etal. Pentanucleotide repeat (TTTTA)n polymorphism in the 5' control region of the apoliprotein (A) gene and atherothrombotic serum lipoprotein(A) concentration, in a pediatric population. Haematologica. 2003; 88:38-39.
22. Pati U, Pati N. Lipoprotein(a), atherosclerosis, and apolipoprotein(a) gene polymorphism. Mol Genet Metab. 2000; 71:87-92.
23. Nascimento H, Silva L, Lourenço P, etal. Lipoprotein(a) levels in obese Portuguese children and adolescents: Contribution of the pentanucleotide repeat (TTTTA)n polymorphism in the apolipoprotein(a) gene. Arch Pediatr Adolesc Med. 2009; 163:393-394.
24. Locatelli F, Aljama P, Barany P, etal. Revised European best practice guidelines for the management of anemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004; 19(Suppl 2):ii1-ii47.
25. Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: An alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens. 1992; 39:225-235.
26. Gaffney D, Campbell RA. A PCR based method to determine the Kalow allele of the cholinesterase gene: The E1k allele frequency and its significance in the normal population. J Med Genet. 1994; 31:248-250.
27. Trommsdorff M, Köchl S, Lingenhel A, etal. A pentanucleotide repeat polymorphism in the 5' control region of the apolipoprotein(a) gene is associated with lipoprotein(a) plasma concentrations in Caucasians. J Clin Invest. 1995; 96:150-157.
28. Helal I, Smaoui W, Hamida FB, etal. Cardiovascular risk factors in hemodialysis and peritoneal dialysis patients. Saudi J Kidney Dis Transpl. 2010; 21:59-62.
29. Belo L, Caslake M, Santos-Silva A, etal. LDL size, total antioxidant status and oxidised LDL in normal human pregnancy: A longitudinal study. Atherosclerosis. 2004; 177:391-399.
30. Graaf J, Hak-Lemmers HLM, Hectors MPC, Demacker PNM, Hendriks JCM, Stalenhoef AFH. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb. 1991; 11:298-306.
31. Costa E, Rocha S, Rocha-Pereira P, etal. Cross-talk between inflammation, coagulation/fibrinolysis and vascular access in hemodialysis patients. J Vasc Access. 2008; 9:248-253.
32. Martin LJ, Woo JG, Daniels SR, Goodman E, Dolan LM. The relationships of adiponectin with insulin and lipids are strengthened with increasing adiposity. J Clin Endocrinol Metab. 2005; 90:4255-4259.
33. Lautamäki R, Rönnemaa T, Huupponen R, etal. Low serum adiponectin is associated with high circulating oxidized low-density lipoprotein in patients with type 2 diabetes mellitus and coronary artery disease. Metabolism. 2007; 56:881-886.
34. Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet. 2000; 356:147-152.
35. Ariyo AA, Thach C, Tracy R. Lp(a) lipoprotein, vascular disease, and mortality in the elderly. N Engl J Med. 2003; 349:2108-2115.
36. Vaughan CJ, Gotto AM Jr. Update on statins: 2003. Circulation. 2004; 110:886-892.